Starling Oncology (STLNW) Non-Current Assets (2019 - 2026)

Starling Oncology (STLNW) has reported Non-Current Assets for 8 consecutive years, with $49.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Assets fell 10.48% year-over-year to $49.2 million; the trailing twelve-month figure through Jun 2026 stood at $206.0 million (down 12.41% YoY), and the FY2025 full-year result was $51.9 million, down 13.91% from the prior year.
• Non-Current Assets slipped to $49.2 million in Q2 2026 per STLNW's latest filing, from $51.4 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $140.2 million in Q3 2022 and bottomed at $49.2 million in Q2 2026.
• Historically, Non-Current Assets has averaged $75.4 million across 5 years, with a median of $63.4 million in 2024.
• The widest YoY moves for Non-Current Assets: up 165.77% in 2022, down 71.05% in 2022.
• Over 5 years, Non-Current Assets stood at $131.2 million in 2022, then sank by 49.91% to $65.7 million in 2023, then declined by 8.29% to $60.3 million in 2024, then slipped by 13.91% to $51.9 million in 2025, then retreated by 5.14% to $49.2 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $49.2 million, $51.4 million, and $51.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.